이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

르네상스 2 : SPN-817 초점 발작이있는 성인의 이중 맹검, 위약 대조 연구

2026년 9월 30일 업데이트: Supernus Pharmaceuticals, Inc.

르네상스 2 : 초점 발작이있는 성인의 SPN-817의 효능, 안전성 및 내약성을 평가하기위한 이중 맹검, 무작위, 위약 대조, 다기관, 병렬 그룹 연구

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.

연구 개요

상세 설명

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 administered as an adjunctive treatment in adults with focal onset seizures that have previously failed at least 2 anti-seizure medication (ASM) regimens. Participants will be taking 1 to 4 ASMs, with at least 4 seizures during the 6-week Screening Period. Following the Screening Period, eligible participants will be randomized 2:1 to SPN-817 (3.0-4.0 mg BID) or placebo and begin the Titration Period (8-10 weeks). In both treatment groups, open-label ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic adverse events [AEs]) will be taken (8 mg oral [PO]) prophylactically approximately 30 minutes before each study medication (SM) dose (ie, BID) during the Titration Period as an antiemetic. After the target dose of 3.0-4.0 mg BID is reached, participants will enter the Maintenance Period (14 weeks). Ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic AEs) may be taken as needed as either a preventative or therapeutic antiemetic during the Maintenance Period. Participants who complete the Maintenance Period will have the opportunity to enroll in a separate open-label study for continued treatment with SPN-817. Participants who do not enroll in the open-label study will undergo a Tapering Period (up to 4 weeks) and a follow-up safety phone call.

연구 유형

중재적

등록 (추정된)

216

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Arizona
      • Phoenix, Arizona, 미국, 85004
        • 모병
        • Xenoscience
      • Phoenix, Arizona, 미국, 85006
        • 모병
        • Banner University Medical Center-Phoenix
      • Tucson, Arizona, 미국, 85724
        • 모병
        • University of Arizona College of Medicine - Tucson
      • Tucson, Arizona, 미국, 85718
        • 모병
        • Center for Neurosciences
    • Arkansas
      • Little Rock, Arkansas, 미국, 72205
        • 모병
        • Clinical Trials, Inc
    • California
      • Los Angeles, California, 미국, 90048
        • 모병
        • Clinical Research Institute
      • Mission Hills, California, 미국, 91345
        • 모병
        • Access Community Clinical Trials
      • Orange, California, 미국, 92868
        • 모병
        • University of California, Irvine
      • West Hills, California, 미국, 91307
        • 모병
        • Focus Clinical Research
    • Connecticut
      • New Haven, Connecticut, 미국, 06510
        • 모병
        • Yale University
    • Florida
      • Gulf Breeze, Florida, 미국, 32561
        • 모병
        • Northwest Florida Clinical Research Group, LLC
      • Kissimmee, Florida, 미국, 34744
        • 모병
        • Ilumina Medical Research
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami
      • Miami, Florida, 미국, 33133
        • 모병
        • Visionary Investigators Network
      • Orlando, Florida, 미국, 32806
        • 종료됨
        • Research Institute of Orlando, LLC
      • Port Charlotte, Florida, 미국, 33952
        • 모병
        • Medsol Clinical Research Center
        • 연락하다:
      • Port Saint Lucie, Florida, 미국, 34990
        • 모병
        • Cleveland Clinic Florida Martin Health
    • Illinois
      • Springfield, Illinois, 미국, 62702
        • 모병
        • Southern Illinois University School of Medicine
    • Kentucky
      • Louisville, Kentucky, 미국, 40223
        • 모병
        • University of Louisville Physicians
    • Louisiana
      • Covington, Louisiana, 미국, 70433
        • 모병
        • Neurocare of Louisiana
      • New Orleans, Louisiana, 미국, 70121
        • 정지된
        • Ochsner Clinic Foundation
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • 모병
        • Johns Hopkins University
      • Bethesda, Maryland, 미국, 20817
        • 모병
        • Mid Atlantic Epilepsy and Sleep Center
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • 모병
        • Wayne State University - Detroit Medical Center
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601
        • 모병
        • Northeast Regional Epilepsy Group - Hackensack
      • Neptune City, New Jersey, 미국, 07753
        • 모병
        • Hackensack Meridian Health Jersey Shore University Medical Center
    • New York
      • Albany, New York, 미국, 12208
        • 모병
        • Albany Medical Center
      • Amherst, New York, 미국, 14226
        • 모병
        • Dent Neurologic Institute
      • New York, New York, 미국, 10021
        • 모병
        • Northwell Health - Lenox Hill
      • Rochester, New York, 미국, 14618
        • 모병
        • University of Rochester Medical Center
    • North Carolina
      • Asheville, North Carolina, 미국, 28806
        • 모병
        • Asheville Neurology Specialists
      • Charlotte, North Carolina, 미국, 28211
        • 모병
        • OnSite Clinical Solutions, LLC
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 모병
        • Neurology Institute Epilepsy Center of Cleveland Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • 모병
        • Thomas Jefferson University
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University Medical Center
    • Texas
      • El Paso, Texas, 미국, 79912
        • 모병
        • Advanced Neurology Epilepsy and Sleep Center/ANESC Research
      • Frisco, Texas, 미국, 75034
        • 모병
        • Stryde Research
      • Houston, Texas, 미국, 77030
        • 모병
        • UT Health Houston
    • Virginia
      • McLean, Virginia, 미국, 22101
        • 모병
        • Medstar Health Research Institute
      • Blagoevgrad, 불가리아, 2700
        • 모병
        • Multiprofile Hospital for Active Treatment PULS
      • Pleven, 불가리아, 5809
        • 모병
        • Medical Center (MC) Academica
      • Rousse, 불가리아, 7012
        • 모병
        • Medical Center - Teodora EOOD
      • Sofia, 불가리아, 1113
        • 모병
        • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "Sveti Naum" EAD
    • Sofia-Grad
      • Sofia, Sofia-Grad, 불가리아, 1431
        • 모병
        • University Multiprofile Hospital for Active Treatment Aleksandrovska, Clinic for Neurology Diseases
      • Lublin, 폴란드, 20-064
        • 모병
        • NZOZ NEUROMED M. and M. Nastaj Spółka Partnerska
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 30-727
        • 모병
        • Pratia MCM Kraków
    • Maloplski
      • Krakow, Maloplski, 폴란드, 30-363
        • 모병
        • Centrum Medyczne Plejady
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 01-684
        • 모병
        • Centrum Medyczne NeuroProtect
      • Warsaw, Masovian Voivodeship, 폴란드, 02-172
        • 모병
        • TZ Clinical Research powered by Pratia
      • Warsaw, Masovian Voivodeship, 폴란드, 02-952
        • 모병
        • Neurosphera
    • Pomeranian Voivodeship
      • Gdynia, Pomeranian Voivodeship, 폴란드, 81-537
        • 모병
        • Synexus Polska Sp. z o. o. Oddział w Gdyni
      • Sopot, Pomeranian Voivodeship, 폴란드, 81-735
        • 정지된
        • Terra Centrum Leczenia
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, 폴란드, 40-123
        • 모병
        • NZOZ Wielospacjalistyczna Poradnia Lekarska Synapsis
      • Katowice, Silesian Voivodeship, 폴란드, 40-650
        • 모병
        • Novo-Med Zieliński i Wsp. Sp.J.
      • Budapest, 헝가리, 1125
        • 모병
        • Flash Clinic
      • Budapest, 헝가리, 1145
        • 모병
        • SE, Idegsebeszeti es Neurointervencios Klinika, Epilepszia Centrum
    • Queensland
      • Herston, Queensland, 호주, 4029
        • 모병
        • Royal Brisbane and Women's Hospital
    • South Australia
      • Adelaide, South Australia, 호주, 5000
        • 모병
        • Royal Adelaide Hospital
    • Victoria
      • Clayton, Victoria, 호주, 3168
        • 모병
        • Monash Medical Centre
      • Fitzroy, Victoria, 호주, 3065
        • 모병
        • St. Vincent's Hospital Melbourne
      • Melbourne, Victoria, 호주, 3004
        • 모병
        • The Alfred Hospital
      • Parkville, Victoria, 호주, 3052
        • 모병
        • Royal Melbourne Hospital
    • Western Australia
      • Nedlands, Western Australia, 호주, 6009
        • 모병
        • The Perron Institute for Neurological and Translational Science

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy Study Consortium, Inc (ESCI);
  2. Failed to achieve sustained seizure freedom after ≥2 tolerated, appropriately chosen, and adequately dosed ASM drug schedules;
  3. Able to keep accurate Seizure electronic diaries [eDiaries] (with the aid of a caregiver as needed);
  4. Has a body mass index (BMI) between 18.0 and 40.0 kg/m2;
  5. Treatment with a stable dose of 1 to 4 current ASMs for ≥28 days prior to screening. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to Visit 1. The diet plan should be maintained throughout the duration of the study;
  6. At least 4 clinically observable focal onset seizures accepted by the ESCI prior to the first dose of SM (during the days of baseline Seizure electronic diary [eDiary] data collection) and no more than a consecutive 21-day period that was free of these seizures. To be eligible for the study, participants must comply with the eDiary on at least 80% of the days of baseline data collection;

Exclusion Criteria:

  1. Has taken huperzine A within the past 6 months;
  2. Prior diagnosis of combined focal and generalized epilepsy syndrome as evidenced by severe developmental delay and multiple seizure types and confirmed by electroencephalography (EEG) (eg, Lennox-Gastaut syndrome). Participants should also be excluded in case of nondiagnostic information;
  3. History of or current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures;
  4. Only has seizures that are difficult to count; for example, seizures that are not clinically observable;
  5. History of uncountable seizures, such as seizures that happen in a cluster that are too rapid to be counted individually;
  6. History of status epilepticus within 6 months prior to screening;
  7. Vagus nerve stimulation, deep brain stimulation, responsive neurostimulator system, or other neurostimulation for epilepsy device implanted or activated within 1 year prior to screening; or epilepsy surgery within 1 year prior to screening. Stimulation parameters for devices must have been stable for at least 3 months prior to Screening. Battery change for any epilepsy devices will be allowed; however, stimulation parameters must remain stable during the duration of the study;
  8. Any suicidal behavior or suicidal ideation related to item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS assessment in the 1 year before screening; a suicide attempt in the last 2 years before screening; or more than 1 lifetime suicide attempt;
  9. Chronic concomitant therapy with non-ASMs that have potent cholinergic (central or peripheral) or potent central (only) anticholinergic pharmacology.
  10. History of >2 allergic reactions to an ASM or 1 serious hypersensitivity reaction to an ASM;
  11. Any other reason which, in the opinion of the Investigator, would prevent the participant from taking part in the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SPN-817

SPN-817, bid

SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

위약 비교기: Placebo

Placebo, bid

Placebo, bid

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period
기간: Baseline and Maintenance Period (Maintenance Week 1-14)

Percent change in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline

Baseline and Maintenance Period (Maintenance Week 1-14)

2차 결과 측정

결과 측정
측정값 설명
기간
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
기간: Baseline and Maintenance Period (Maintenance Week 1-14)

Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline.

Baseline and Maintenance Period (Maintenance Week 1-14)
PCH from baseline in focal onset seizure frequency per 28 days over the entire Treatment Period
기간: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

Percent change in 28-day frequency of focal seizures during the entire Treatment Period (Titration Period + Maintenance Period) relative to baseline

Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
기간: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the Treatment Period (Titration Period + Maintenance Period) relative to baseline.

Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
Longest seizure-free interval over the entire Treatment Period
기간: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14

The longest intervals in days between two seizures during the entire Treatment Period.

Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
Incidence of treatment-emergent adverse events (TEAEs)
기간: Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4

The percent of subjects who took at least one dose of SPN-817 and reported at least one adverse event during SPN-817 treatment.

Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Maciej Gasior, MD, PhD, Supernus Pharmaceuticals, Inc.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 30일

기본 완료 (추정된)

2027년 8월 1일

연구 완료 (추정된)

2027년 8월 1일

연구 등록 날짜

최초 제출

2025년 1월 16일

QC 기준을 충족하는 최초 제출

2025년 1월 27일

처음 게시됨 (실제)

2025년 1월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다